{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=48&q=hormone+receptor-positive", "query": { "q": "hormone receptor-positive", "condition": "Breast Cancer", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 679, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=49&q=hormone+receptor-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=47&q=hormone+receptor-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T20:07:51.405Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06884254", "title": "Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "EG1206A", "type": "DRUG" }, { "name": "Perjeta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EirGenix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2025-05", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06884254" }, { "nct_id": "NCT03330405", "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors" ], "interventions": [ { "name": "Avelumab Phase 1b", "type": "DRUG" }, { "name": "Talazoparib Phase 1b", "type": "DRUG" }, { "name": "Avelumab Phase 2", "type": "DRUG" }, { "name": "Talazoparib Phase 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 223, "start_date": "2017-10-19", "completion_date": "2023-01-04", "has_results": true, "last_update_posted_date": "2023-10-13", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 38, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330405" }, { "nct_id": "NCT06264921", "title": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Tumor, Adult", "Advanced Solid Tumor", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Cancer", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer" ], "interventions": [ { "name": "NKT3447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2024-02-23", "completion_date": "2025-04-16", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06264921" }, { "nct_id": "NCT01958021", "title": "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced, Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 668, "start_date": "2013-12-17", "completion_date": "2023-03-16", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 73, "location_summary": "Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01958021" }, { "nct_id": "NCT02778685", "title": "Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 47, "start_date": "2016-09-30", "completion_date": "2026-03-30", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 7, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 4 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02778685" }, { "nct_id": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer", "Breast Cancer", "Breast Carcinoma", "Cancer of the Breast", "Cancer of Breast", "Malignant Tumor of Breast", "Breast Tumor" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 5, "location_summary": "Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Canton", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05191004" }, { "nct_id": "NCT00283608", "title": "Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Single nucleotide polymorphism (SNP)", "type": "GENETIC" }, { "name": "high performance liquid chromatography", "type": "OTHER" }, { "name": "measurements by DXA", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1000, "start_date": "2005-07", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2011-05-16", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283608" }, { "nct_id": "NCT07460752", "title": "Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Locally Advanced Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 98, "start_date": "2026-05-22", "completion_date": "2029-06-21", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07460752" }, { "nct_id": "NCT06065748", "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "FoundationOne Liquid CDx Assay (F1LCDx)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1050, "start_date": "2023-12-11", "completion_date": "2029-02-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 40, "location_summary": "Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Harbor City", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065748" }, { "nct_id": "NCT00755313", "title": "Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Fatigue", "Long-term Effects Secondary to Cancer Therapy in Adults", "Neurotoxicity", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "aromatase inhibition therapy", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "metabolic assessment", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "study of socioeconomic and demographic variables", "type": "OTHER" }, { "name": "cognitive assessment", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "35 Years to 80 Years · Female only" }, "enrollment_count": 81, "start_date": "2007-05", "completion_date": "2014-06-06", "has_results": false, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-10-21T20:07:51.405Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00755313" } ] }